8-K: Bioxytran Acquires NDPD Pharma in Stock Deal Valued at $15.85 Million

Bioxytran, Inc. has acquired NDPD Pharma, Inc. in a stock transaction valued at $15.85 million, gaining control of patents for a promising antiviral compound.

Summary

• Bioxytran, Inc. acquired 100% of NDPD Pharma, Inc. on October 25, 2024.
• The acquisition was completed through a stock purchase agreement, with Bioxytran issuing 3,389,169 common shares to non-affiliates and 28,467,564 preferred shares to affiliates.
• The total purchase price was valued at $15.85 million.
• The valuation of the shares was based on the Volume-Weighted Average Price (VWAP) of Bioxytran's common stock as of the last trading day prior to October 1, 2024.
• NDPD Pharma held patents for ProLectin-M (PLM), a compound with potential applications in treating various viral infections.
• The fair market value of the license agreement for PLM was appraised at $8.19 million.
• NDPD also held 14,085,410 shares of Bioxytran Preferred Stock, which were subsequently canceled and returned to treasury.
• The acquisition includes intangible assets related to the patents and the license agreement, which are being amortized over 18 years.
• Goodwill of $5,382,610 was recorded as part of the acquisition.

Sentiment

Score: 7

Explanation: The acquisition is a positive development for Bioxytran, providing access to valuable intellectual property. However, the presence of goodwill and the need for amortization introduce some financial risks. The sentiment is moderately positive.

Positives

• Bioxytran gains control of valuable patents for ProLectin-M, a compound with potential for treating multiple viral infections.
• The acquisition is expected to enhance Bioxytran's scientific expertise and service solutions.
• The fair market value of the acquired assets is equal to the purchase price.
• The acquisition was unanimously approved by Bioxytran's Board of Directors.

Negatives

• The acquisition resulted in the recording of $5,382,610 in goodwill, which is not tax deductible.
• The intangible assets are being amortized over 18 years, which will impact future earnings.
• The company has assumed a loan from an affiliate of $12,506.

Risks

• The success of ProLectin-M is subject to regulatory and commercial risks.
• The valuation of the intangible assets is based on estimated future cash flows, which may not materialize.
• Goodwill is subject to impairment testing, which could result in future losses.
• The company has assumed a loan from an affiliate of $12,506.

Future Outlook

The company expects to amortize the intangible assets over 18 years and will test goodwill for impairment at least annually. The company will also disclose transactions executed under the 10b5-1 plan through Form 4 filings.

Management Comments

• The Board of Directors unanimously voted to acquire 100% of the issued and outstanding shares of Common Stock of NDPD Pharma, Inc.

Industry Context

The acquisition of NDPD Pharma aligns with the broader trend of pharmaceutical companies seeking to expand their pipelines through strategic acquisitions of promising drug candidates and technologies. The focus on antiviral treatments is particularly relevant given the ongoing global health concerns related to infectious diseases.

Comparison to Industry Standards

• The valuation of the license agreement at $8.19 million is based on a discounted cash flow analysis, a common method used in the pharmaceutical industry for valuing intellectual property.
• The 40% discount rate applied to the royalty cash flows reflects the high risk associated with drug development and commercialization, which is typical in the biotech sector.
• The amortization of intangible assets over 18 years is consistent with accounting practices for similar assets in the pharmaceutical industry.
• The recording of goodwill is a standard accounting practice in business combinations where the purchase price exceeds the fair value of net assets acquired.

Related Party Transactions

• The acquisition of NDPD Pharma involved related parties as Bioxytran's officers had beneficial ownership in NDPD Pharma.

Stakeholder Impact

• Shareholders of Bioxytran will see a change in the company's asset base and future prospects.
• Employees of Bioxytran may see changes in their roles and responsibilities.
• Customers and suppliers may see changes in the company's product offerings and supply chain.
• Creditors may see changes in the company's financial position.

Next Steps

• Bioxytran will amortize the intangible assets over 18 years.
• The company will test goodwill for impairment at least annually.
• Ola Soderquist will sell 500,000 shares of common stock under a 10b5-1 trading plan.
• The company will disclose transactions executed under the 10b5-1 plan through Form 4 filings.

Key Dates

Keywords

acquisition, NDPD Pharma, Bioxytran, ProLectin-M, patents, antiviral, stock purchase, intangible assets, goodwill, license agreement